[go: up one dir, main page]

GB201114923D0 - Immunogenic proteins and compositions - Google Patents

Immunogenic proteins and compositions

Info

Publication number
GB201114923D0
GB201114923D0 GB201114923A GB201114923A GB201114923D0 GB 201114923 D0 GB201114923 D0 GB 201114923D0 GB 201114923 A GB201114923 A GB 201114923A GB 201114923 A GB201114923 A GB 201114923A GB 201114923 D0 GB201114923 D0 GB 201114923D0
Authority
GB
United Kingdom
Prior art keywords
compositions
immunogenic proteins
streptococcus
proteins
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201114923A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GB201114923A priority Critical patent/GB201114923D0/en
Publication of GB201114923D0 publication Critical patent/GB201114923D0/en
Priority to PCT/IB2012/054464 priority patent/WO2013030783A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).
GB201114923A 2011-08-30 2011-08-30 Immunogenic proteins and compositions Ceased GB201114923D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201114923A GB201114923D0 (en) 2011-08-30 2011-08-30 Immunogenic proteins and compositions
PCT/IB2012/054464 WO2013030783A1 (en) 2011-08-30 2012-08-30 Immunogenic proteins and compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201114923A GB201114923D0 (en) 2011-08-30 2011-08-30 Immunogenic proteins and compositions

Publications (1)

Publication Number Publication Date
GB201114923D0 true GB201114923D0 (en) 2011-10-12

Family

ID=44838893

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201114923A Ceased GB201114923D0 (en) 2011-08-30 2011-08-30 Immunogenic proteins and compositions

Country Status (2)

Country Link
GB (1) GB201114923D0 (en)
WO (1) WO2013030783A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108064174A (en) * 2014-08-05 2018-05-22 葛兰素史密丝克莱恩生物有限公司 Antigen Carrier Molecule

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NL8802046A (en) 1988-08-18 1990-03-16 Gen Electric POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
DK1005368T3 (en) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
KR20010042573A (en) 1998-04-09 2001-05-25 장 스테판느 Adjuvant compositions
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
DE122009000054I1 (en) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa VACCINE AGAINST BACTERIAL ANTIGENE
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
ES2335979T3 (en) 2001-09-14 2010-04-07 Cytos Biotechnology Ag IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE.
JP4360906B2 (en) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー In vivo activation of antigen-presenting cells to enhance the immune response induced by virus-like particles
ATE414535T1 (en) 2003-06-23 2008-12-15 Baxter Int CARRIER PROTEINS FOR VACCINES
CA2537742C (en) * 2003-09-15 2014-07-22 Chiron Corporation Immunogenic compositions for streptococcus agalactiae
US20090317420A1 (en) * 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2586058A1 (en) 2004-11-01 2006-05-11 Dennis L. Kasper Modified streptococcal polysaccharides and uses thereof
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
WO2006130328A2 (en) 2005-05-13 2006-12-07 Novartis Vaccines And Diagnostics, Inc. Serum resistance factors of gram positive bacteria
UA95237C2 (en) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. IMMUNOGENIC COMPOSITION
WO2009027768A2 (en) * 2006-07-26 2009-03-05 Novartis Ag Immunogenic compositions for gram positive bacteria
GB0802503D0 (en) 2008-02-11 2008-03-19 Novartis Ag Hybrid polypeptide
AU2010204139A1 (en) * 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB201003333D0 (en) * 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions

Also Published As

Publication number Publication date
WO2013030783A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
MX349948B (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae.
EP4414376A3 (en) Novel depsipeptide and uses thereof
IN2014DN10670A (en)
SG10201903119QA (en) Polypeptide vaccine
PH12012502452A1 (en) Vectors and sequences for the treatment of diseases
NZ730763A (en) Methods of treating a tauopathy
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12014501991B1 (en) Phenicol antibacterials
IN2015DN01156A (en)
NZ707086A (en) Anti-cd40 antibodies and methods of use
EP4450130A3 (en) Formulations of enzalutamide
GB201118656D0 (en) New compounds
MX366899B (en) New compounds.
PH12014500904B1 (en) Antibody formulations and methods
IN2014DN10386A (en)
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
IN2014MN02236A (en)
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
CA2843611C (en) Compositions and methods for reducing the incidence of equine digestive disorders
MX2015008486A (en) Compositions and methods for treating bacterial infections.
IN2014DN03010A (en)
IN2015DN02109A (en)
MA40642A (en) Novel peptide derivatives and uses thereof
WO2020022975A3 (en) New pharmaceutical compositions in the treatment of copd

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)